- Home
- MAIA vs LVTX Comparison
MAIA vs LVTX Comparison
Compare MAIA & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | LVTX |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 40.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAIA | LVTX |
|---|---|---|
| Price | $1.12 | $1.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.58 |
| AVG Volume (30 Days) | ★ 224.1K | 131.8K |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,990,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.85 |
| 52 Week High | $2.74 | $2.00 |
Technical Indicators
Market Signals| Indicator | MAIA | LVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 62.46 |
| Support Level | $0.87 | $1.60 |
| Resistance Level | $1.09 | $1.83 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 86.21 | 65.28 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.